Antiproliferative strategies for the treatment of vascular proliferative disease
- PMID: 15320855
- DOI: 10.2174/1570161033386763
Antiproliferative strategies for the treatment of vascular proliferative disease
Abstract
Excessive cellular proliferation contributes to the pathobiology of vascular obstructive diseases (e.g., atherosclerosis, in-stent restenosis, transplant vasculopathy, and vessel bypass graft failure). Therefore, anti-proliferative therapies may be a suitable approach in the treatment of these disorders. Candidate targets for such strategies include the cyclin-dependent kinase/cyclin holoenzymes, members of the cyclin-dependent kinase family of inhibitory proteins, tumor suppressors, growth factors and transcription factors that control cell cycle progression. In this review, we will discuss the use of pharmacological agents and gene therapy approaches targeting cellular proliferation in animal models and clinical trials of cardiovascular disease.
Similar articles
-
Inhibiting cyclin-dependent kinase/cyclin activity for the treatment of cancer and cardiovascular disease.Curr Pharm Biotechnol. 2003 Feb;4(1):21-37. doi: 10.2174/1389201033377977. Curr Pharm Biotechnol. 2003. PMID: 12570680 Review.
-
Control of vascular smooth muscle cell growth by cyclin-dependent kinase inhibitory proteins and its implication in cardiovascular disease.Front Biosci. 2000 Jul 1;5:D619-28. doi: 10.2741/sanz. Front Biosci. 2000. PMID: 10877996 Review.
-
Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury.FASEB J. 2004 Aug;18(11):1285-7. doi: 10.1096/fj.04-1646fje. Epub 2004 Jun 4. FASEB J. 2004. PMID: 15180955
-
Cutting balloon combined with paclitaxel-eluting balloon for treatment of in-stent restenosis.Arch Cardiovasc Dis. 2013 Feb;106(2):79-85. doi: 10.1016/j.acvd.2012.10.004. Epub 2013 Jan 30. Arch Cardiovasc Dis. 2013. PMID: 23527911
-
Valproic acid inhibits proliferation of human coronary vascular cells (SI/MPL-ratio: 0.5): a novel candidate for systemic and local therapy of postinterventional restenosis.Coron Artery Dis. 2010 Aug;21(5):286-91. doi: 10.1097/MCA.0b013e3283349cd7. Coron Artery Dis. 2010. PMID: 20508518
Cited by
-
Activatory properties of lysophosphatidic acid on human THP-1 cells.Inflammation. 2007 Oct;30(5):167-77. doi: 10.1007/s10753-007-9034-2. Inflammation. 2007. PMID: 17594136
-
Activatory properties of lysophosphatidic acid on human THP-1 cells.Inflammation. 2005 Dec;29(4-6):129-40. doi: 10.1007/s10753-006-9008-9. Epub 2006 Nov 7. Inflammation. 2005. PMID: 17089191
-
Trichostatin A enhances proliferation and migration of vascular smooth muscle cells by downregulating thioredoxin 1.Cardiovasc Res. 2010 Jan 1;85(1):241-9. doi: 10.1093/cvr/cvp263. Cardiovasc Res. 2010. PMID: 19633316 Free PMC article.
-
Effects of paclitaxel intervention on pulmonary vascular remodeling in rats with pulmonary hypertension.Exp Ther Med. 2019 Feb;17(2):1163-1170. doi: 10.3892/etm.2018.7045. Epub 2018 Dec 5. Exp Ther Med. 2019. PMID: 30679989 Free PMC article.
-
Thiamylal sodium increased inflammation and the proliferation of vascular smooth muscle cells.Korean J Anesthesiol. 2016 Jun;69(3):262-9. doi: 10.4097/kjae.2016.69.3.262. Epub 2016 Jun 1. Korean J Anesthesiol. 2016. PMID: 27274372 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources